Kofarest Syrup is a combination expectorant and bronchodilator formulation containing Ambroxol (30 mg/5 ml), Guaifenesin (100 mg/5 ml), and Terbutaline (2.5 mg/5 ml). Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency. Guaifenesin serves as an expectorant, promoting the thinning and loosening of mucus to enhance productive cough and facilitate expectoration. Terbutaline, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscle, thus alleviating bronchospasm and improving airflow in obstructive airway conditions. Kofarest Syrup is indicated for the symptomatic management of respiratory disorders characterized by excessive or thick mucus production and bronchoconstriction, such as acute and chronic bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). The combined pharmacological actions result in improved mucus clearance and relief of airway obstruction, contributing to enhanced respiratory function and patient comfort. The syrup formulation allows for easy administration, particularly in pediatric and adult patients with difficulty swallowing tablets. Use of Kofarest Syrup should be under medical supervision, with attention to contraindications such as hypersensitivity to components, cardiovascular disorders, and caution in patients with diabetes or hyperthyroidism. Adverse effects may include gastrointestinal disturbances, tremors, or palpitations, and patients should be monitored accordingly.